Program
Bosentan
Also written as “bosentan”, “Bosentan 125 mg” and “Bosentan 62.5 mg”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Idiopathic Pulmonary Fibrosis · digital ulcers · Scleroderma, Systemic, led by 5 companies.
Drug pageBosentan: every studyMany companies study it; this page follows only the 30 they lead. All 85 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 260 open or running | phase 4since Apr 30, 2004 | Oct 6, 2003 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Sep 23, 2019 | Sep 23, 2019 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since May 20, 2013 | May 20, 2013 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jun 26, 2024 | Jun 26, 2024 | none ahead |
| Retinset SL | 10 open or running | phase 1since Aug 22, 2019 | Aug 22, 2019 | none ahead |
Also a collaborator on its studies: Dong-A ST.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Retinset SL only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 22, 2019First study: phase 1 study in Diabetes MellitusFirst studyNCT04068272 · 22 enrolled · Spain
TargetBeta
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| aprocitentanrule | Idorsia Pharmaceuticals | phase 3 | 14 |
Studies
The one study Retinset SL leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04068272Diabetes Mellitus · Spain | 1 | Completed | May 20, 2022 | 22 |
How it is read
Names in the registry
- “Bosentan”, 19 entries
- “bosentan”, 12 entries
- “Bosentan 125 mg”, 3 entries
- “Bosentan 62.5 mg”, 2 entries
- “Bosentan Dispersible Tablets”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 14 studies
- Hypertension, Pulmonary, 6 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- digital ulcers, 2 studies
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.